PMID: 8971369Dec 1, 1996Paper

Effective treatment of relapsing experimental autoimmune encephalomyelitis with pseudoautologous bone marrow transplantation

Bone Marrow Transplantation
M van Gelder, D W van Bekkum

Abstract

Several human and experimental autoimmune diseases, including the current model for multiple sclerosis (MS), ie relapsing experimental autoimmune encephalomyelitis (R-EAE), have been reported to respond with complete remission to lympho- and myeloablation and rescue with transplantation of bone marrow (BMT) from healthy donors. Since treatment with autologous BM was as effective in our arthritis model as treatment with allogeneic BM from healthy rats, and in view of the much lower risk of autologous BMT in clinical practice, we have investigated treatment of R-EAE with pseudo-autologous (PSA) BM. PSABM is harvested from animals in the same active stage of R-EAE as the syngeneic recipients which are to be treated. Our results show that PSABM is as effective as syngeneic BM, except for a higher incidence of artificially induced relapses. We also demonstrated that lymphocytes present in the autologous BM graft may contribute to the occurrence of relapses post-transplantation. The implications of our results for a possible clinical application in the treatment of MS patients are discussed. If such treatment is envisaged, the use of T cell-depleted autografts seems mandatory, particularly as human BM contains 10 times more lymphocyt...Continue Reading

References

Jun 1, 1977·Arthritis and Rheumatism·J L BaldwinM Mannik
Oct 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·P J TienariJ Palo
Feb 1, 1991·Journal of Neuroscience Research·W F HickeyH Kimura
Jun 1, 1990·Scandinavian Journal of Immunology·J KampingaR Aspinall
Jul 1, 1988·Neurology·M F Mendez, S Pogacar
Nov 1, 1994·The Journal of Experimental Medicine·M K RackeM Röcken
Jan 29, 1994·Lancet·G C Ebers
Jan 1, 1994·Journal of Neurology, Neurosurgery, and Psychiatry·R A Hughes
Feb 1, 1993·Annals of Neurology·J W PrineasE S Cho

❮ Previous
Next ❯

Citations

Nov 15, 2002·International Journal of Hematology·Richard K BurtAlberto M Marmont
Jul 18, 2001·Springer Seminars in Immunopathology·J Moore, P Brooks
Oct 15, 2003·Blood Reviews·Athanasios Fassas, Vassilios K Kimiskidis
Sep 21, 2000·Critical Reviews in Oncology/hematology·N SabaA Keating
Aug 10, 1999·Critical Reviews in Oncology/hematology·A Gratwohl, A Tyndall
Oct 20, 2006·International Journal of Hematology·Li SuDao-Pei Lu
Aug 7, 2012·Current Diabetes Reports·Carlos Eduardo Barra CouriBelinda Pinto Simões
Dec 21, 2000·Current Rheumatology Reports·F ViganegoD E Furst
Dec 20, 2005·Journal of Neurology, Neurosurgery, and Psychiatry·J P A SamijnR Q Hintzen
Oct 25, 2008·Arthritis Research & Therapy·Thomas Hügle, Jacob M van Laar
Jan 16, 2010·ILAR Journal·Valerie L Joers, Marina E Emborg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.